Unilife (UNIFF) 8-K Unilife Corporation Announces Financial Results

Fiscal Year 2014 1

st

Quarter Earnings Call

November 11, 2013

1

Exhibit

99.2

2

This

presentation

contains

forward

looking

statements

under

the

safe

harbor

provisions

of

the

US

securities

laws.

These

forward-looking

statements

are

based

on

management’s

beliefs

and

assumptions

and

on

information

currently

available

to

our

management.

Our

management

believes

that

these

forward-looking

statements

are

reasonable

as

and

when

made.

However

you

should

not

place

undue

reliance

on

any

such

forward

looking

statements

as

these

are

subject

to

risks

and

uncertainties.

Please

refer

to

our

press

releases

and

our

SEC

filings

for

more

information

regarding

the

use

of

forward

looking

statements.

Cautionary

Note

Regarding

Forward-Looking

Statements

Introductory Comments by Unilife CEO Alan Shortall

3

Entered period of long-term partnerships and rapid revenue growth

Received $5MM Sanofi payment (deferred revenue in Sep 30, 2013 balance sheet)

Beginning to receive payments from other customers for active programs

Sequential quarterly growth anticipated in Fiscal Year 2014

Significant annual growth year over prior year in Fiscal Year 2014 and beyond

Today’s contract with MedImmune for ReadyToGo™

wearable injectors

Continued expansion of product portfolio and commercial pipeline

All customer programs on track irrespective of ‘nuisance’

lawsuits

The Market for Wearable Injectors

Estimated 350 million wearable injectors to be

sold annually by 2024

$20 -

$35 ASP /unit likely to translate into a

market size of $8.8 billion by 2024

Projected CAGR of 138% from 2015 -

2020 and

48% from 2020 –

2024

More than 110 high viscous and large volume

marketed and / or pipeline biologics being

developed for use with wearable injectors

Multiple therapy areas targeted including

cancer and auto-immune diseases

4

Source: Roots Analysis: Bolus Injectors Market, 2014 – 2024, Global License

ReadyToGo™

Platform of Wearable Injectors

5

Pre-Filled. Pre-Assembled. Ready-to-Inject.

Precision-Therapy™

Flex-Therapy™

For long-duration therapies that require

delivery of large dose volumes

For long-duration therapies that require delivery of

large dose volumes with a specific rate profile

Supply Contract with MedImmune

MedImmune is the global biologics R&D arm of AstraZeneca

One of the richest biologic portfolios in the industry

120 large molecule drugs in R&D (half of AstraZeneca’s total clinical pipeline)

Under this agreement,  Unilife will customize and supply devices

from

its platform of wearable injectors for use with target molecules

Several drugs may be selected for use with Unilife's wearable injectors

Unilife selected after an extensive evaluation process

Unilife begins generating revenue in 1Q FY2014

6

Financial Data

7

1Q FY2014

1Q FY2013

Revenues

$3.2MM

$0.7MM

Research & development

$6.4MM

$4.7MM

Selling, general & administrative

$6.5MM

$6.6MM

Net loss

$11.2MM

$12.5MM

Net loss per share –

diluted

$0.12

$0.16

Adjusted net loss

$7.1MM

$9.1MM

Adjusted net loss per share -

diluted

$0.08

$0.12

Moving Forward

Focused on rapid and significant growth in the long-term

Anticipating sequential quarterly growth in FY2014

Annual growth year over prior year in FY2014 and beyond

Continuing to increase investment in R&D and operations

Much of our operating expenditure to be offset by increasing revenue

Can be cash flow positive this year if we wanted to do so, but this not in the best

long-term interests of shareholders

Limiting R&D investment today can dampen future growth and slow programs

Committed to attaining a position of global leadership for injectable

drug delivery systems

8

Fiscal Year 2014 1st

Quarter Earnings Call

Questions

9